Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 1/20 | 0.38 |
| ▸ | FAAH | O00519 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | DHODH | Q02127 | 4/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2725469 | 1.00 | NAAA (0.38) | NAAAFAAHHTTOPRM1DHODH | |
| SCHEMBL2726471 | 0.86 | DHODH (0.33) | OPRM1DHODH | |
| SCHEMBL2725883 | 0.85 | DHODH (0.36) | OPRM1DHODH | |
| SCHEMBL2728330 | 0.85 | DHODH (0.36) | OPRM1DHODH | |
| SCHEMBL2728334 | 0.85 | DHODH (0.36) | OPRM1DHODH | |
| SCHEMBL2725884 | 0.85 | DHODH (0.36) | OPRM1DHODH | |
| SCHEMBL2725233 | 0.85 | DHODH (0.36) | OPRM1DHODH | |
| SCHEMBL2725229 | 0.85 | DHODH (0.36) | OPRM1DHODH | |
| SCHEMBL3908788 | 0.83 | OPRM1 (0.45) | FAAHOPRM1 | |
| SCHEMBL3900975 | 0.83 | OPRM1 (0.45) | FAAHOPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9737504-B2 | Dihydroorotic and acid dehydrogenase inhibitor | INSTITUTE OF MITOCHONDRIA SCIENCE, INC. (JP) | 2017-08-22 | — | — | US | disclosed |
| US-20160296494-A1 | DIHYDROOROTIC AND ACID DEHYDROGENASE INHIBITOR | NAI INC. | 2016-10-13 | — | — | US | disclosed |
| US-9440913-B2 | Dihydroxybenzene derivatives and antiprotozoal agent comprising same as active ingredient | NAI INC. (JP) | 2016-09-13 | — | — | US | disclosed |
| US-20150166498-A1 | DIHYDROOROTIC ACID DEHYDROGENASE INHIBITOR | NAI INC. (JP) | 2015-06-18 | — | — | US | disclosed |
| EP-2857010-A1 | DIHYDROOROTIC ACID DEHYDROGENASE INHIBITOR | NAI Inc. (JP) | 2015-04-08 | — | — | EP | disclosed |
| WO-2013180140-A1 | DIHYDROOROTIC ACID DEHYDROGENASE INHIBITOR | エヌエーアイ株式会社 (JP) | 2013-12-05 | — | — | WO | disclosed |
| US-20130296422-A1 | Novel Dihydroxybenzene Derivatives and Antiprotozoal Agent Comprising Same as Active Ingredient | ARIGEN PHARMACEUTICALS, INC. (JP) | 2013-11-07 | — | — | US | disclosed |
| EP-2636663-A1 | NOVEL DIHYDROXYBENZENE DERIVATIVES AND ANTIPROTOZOAL AGENT COMPRISING SAME AS ACTIVE INGREDIENT | aRigen Pharmaceuticals, Inc. (JP) | 2013-09-11 | — | — | EP | disclosed |
| WO-2012060387-A1 | NOVEL DIHYDROXYBENZENE DERIVATIVES AND ANTIPROTOZOAL AGENT COMPRISING SAME AS ACTIVE INGREDIENT | アリジェン製薬株式会社 (JP) | 2012-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150166498-A1 | DIHYDROOROTIC ACID DEHYDROGENASE INHIBITOR | DHODH, DPYD, DLD | NAAA 1924/4885FAAH 1902/4885HTT 1020/4885 |
| US-20130296422-A1 | Novel Dihydroxybenzene Derivatives and Antiprotozoal Agent Comprising Same as Active Ingredient | CBR3, CBR1, DHX35 | NAAA 3009/4885FAAH 1652/4885HTT 4388/4885 |
| US-20160296494-A1 | DIHYDROOROTIC AND ACID DEHYDROGENASE INHIBITOR | DHODH, DPYD, DLD | NAAA 1947/4885FAAH 1770/4885HTT 1123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.